Key Takeaways for Doximity Stock as of August 2026
- Revenue Reacceleration: Q1 revenue climbed to $156.62M, up 7% YoY and past the high end of guidance, while adjusted EBITDA of $74.77M held a 48% margin.
- Guidance Raised: Management lifted full-year revenue guidance by $6M to $671M-$681M, with newly signed AI search contracts, not the legacy pharma business, driving the increase.
- AI Study Win: Doximity Ask posted the lowest error rate, 4.8%, among 24 clinical models in the independent NOHARM study.
- Usage Surge: Quarterly active workflow prescribers grew more than 30% YoY and AI prompt volume rose more than 25% QoQ, with Scribe note-taking users up tenfold in July.
AI Search Reset the Thesis for Doximity Stock After a 69% Collapse
Doximity (DOCS) reported fiscal first-quarter 2027 results on August 6, and the numbers arrived against a stock that had lost 69% of its value over the prior year. Revenue reaccelerated to $156.62 million, up 7% year over year, clearing the high end of the company’s own guidance by 3%. Adjusted EBITDA of $74.77 million came in 8% above the top of guidance, holding a 48% margin.
The reacceleration reset how the market values Doximity stock, and the cause sits in one product. Doximity launched AI search, its clinical advertising tool for pharma, in late April. The company recognized no AI search revenue in the quarter, yet the client conversations it opened drove the beat, and the newly signed contracts fund the raise. Management lifted full-year revenue guidance by $6 million to a range of $671 million to $681 million and set fiscal 2027 adjusted EBITDA guidance at $309 million to $329 million.
Validation came from outside the building. A Stanford and Harvard team published NOHARM, the first large independent trial pitting 24 clinical AI models against 1,100 real patient cases, and Doximity Ask logged the lowest clinical error rate at 4.8%, against 13.6% for the next-best U.S. model. That result carries weight where it counts, because hospital AI committees hold legal liability for a wrong answer, and they buy accordingly. Doximity now has 165 signed health system clients, with recent wins at Northwestern and Penn Medicine.
Quarterly active workflow prescribers grew more than 30% year over year, with nearly half of them using the AI tools, and AI prompt volume climbed more than 25% from the prior quarter. Asked what all that usage costs to serve, CEO Jeff Tangney put the math plainly on the Q1 earnings call: “we’re earning more than 10x per search in revenue than it cost us to run that today.” He expects that cost to fall as models grow more efficient, pushing the new product’s margins toward the company’s existing levels or better.
The quarter carried real drag. Gross margin slipped to 88% from 91% as Doximity raised AI compute spend, and the company guided second-quarter revenue to $170 million to $171 million, a slim 1% gain against last year’s elevated 23% comparison. Most AI search revenue lands in the third quarter. Management calls fiscal 2027 its investment year, and this print is the market’s verdict that the investment is worth funding.
Doximity earns 10 times more per AI search than it costs to run one, yet booked no search revenue last quarter. Track the Q3 ramp on TIKR for free →
TIKR Values Doximity Stock at $31, Well Below Last Year’s Highs
TIKR’s mid-case model values Doximity stock at $31 by March 2031, implying 52% total return from the current price of $21, or 9% annualized over the next 4.6 years.
A 9% annualized return on a former high-growth software name signals a market still pricing Doximity stock for slow-and-steady, not the reacceleration the quarter hinted at.
The path to $31 runs through the AI search ramp. If the contracts recognized in the third quarter carry the ten-times-cost economics management described, the margin drag from this investment year reverses, and the model’s mid-single-digit growth assumption starts to look conservative against 30% prescriber growth. That distance between a beaten-down price and an improving operating story is the whole case.
TIKR’s model sees 52% upside to $31 if Doximity’s AI search delivers. Pressure-test the assumptions yourself on TIKR for free →
Should You Invest in Doximity, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Doximity, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Doximity, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze DOCS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
